CheckPath AML 2018

Course overview

The CheckPath AML 2018 educational activity is a combination virtual slide/digital image-based assessment program in which 4 cases of MDS-diagnostic entities are presented online. Participants will receive peer-reviewed interpretations for each case and demographically-based laboratory and individual participant reports with peer-to-peer comparisons There have been significant advances in the diagnosis and management of AML, which warrant ongoing education for the interdisciplinary care team involved in the management of patients with AML. CheckPath AML 2018 is part of an educational initiative in MDS and AML that will provide guidance to the interdisciplinary care team on the optimal diagnosis and classification of AML, risk stratification, familiarity with cytogenetic and molecular testing, testing algorithms, and individualized treatment selection, assessment of treatment responses, monitoring for and mitigation of adverse events, and patient education regarding prognosis and treatment choices. Upon answer submission, each participant will receive a full diagnostic interpretation, focusing on differential diagnoses and the importance of molecular cytogenetics. The activity offers 4 CME, CMLE, or SAMs CME credits. In addition, the activity also meets requirements for MOC Part IV Performance in Practice Learning Objectives: • Assess diagnostic skills and differential diagnoses relevant to the study cases presented in AML. • Evaluate appropriate ancillary testing methodology relevant to the study cases in AML. • Identify areas of the practice of AML relevant to the study cases where criteria or classification may have undergone recent changes, new disease entities may have emerged, or where new developments involving pathologic work up may impact therapy. • Appropriately interpret AML testing on the basis of available evidence/guidance • Identify cytogenetic and molecular tests that must be performed when diagnosing AML • Effectively use tools for classification and risk stratification, based on morphological, clinical, and genetic criteria • Apply best practices in communications within the clinical care team to ensure optimal diagnosis and treatment for patients with AML, from screening to ongoing post-treatment evaluation and clinical management • Formulate a management plan that delineates scheduled time for patient discussions regarding symptom management and important aspects of care and emotional wellbeing, including referral to appropriate resources The American Society for Clinical Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement The ASCP designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity. These activities also meet MOC Part II Lifelong Learning and Self-Assessment Module (SAMs CME) requirements. ASCP designates these enduring materials for a maximum of 4.0 CMLE credits. These activities meet CMP and state re-licensure requirements for laboratory personnel. For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. Method of Participation To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line. Funded by an independent educational grant from the Celgene Corporation.